AU669335B2 - New conjugates for the introduction of nucleic acid into higher eukaryotic cells - Google Patents
New conjugates for the introduction of nucleic acid into higher eukaryotic cellsInfo
- Publication number
- AU669335B2 AU669335B2 AU25932/92A AU2593292A AU669335B2 AU 669335 B2 AU669335 B2 AU 669335B2 AU 25932/92 A AU25932/92 A AU 25932/92A AU 2593292 A AU2593292 A AU 2593292A AU 669335 B2 AU669335 B2 AU 669335B2
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- eukaryotic cells
- higher eukaryotic
- conjugates
- introduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Conjugates in which a virus is bound via an antibody to a substance with affinity for nucleic acids in order to transport gene constructs into higher eukaryotic cells. Complexes of the conjugates and nucleic acid are, where appropriate with the cooperation of a cell type-specific internalisation factor, internalised into the cell, where the virus, as constituent of the complex, brings about the internalisation as well as the release of the contents of the endosomes in which the complexes are located after entry into the cell. Pharmaceutical compositions in which the nucleic acid is a therapeutically effective gene construct, especially for use in gene therapy, and transfection kits. <IMAGE>
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76778791A | 1991-09-30 | 1991-09-30 | |
US767787 | 1991-09-30 | ||
US82704992A | 1992-01-30 | 1992-01-30 | |
US827049 | 1992-01-30 | ||
US86475892A | 1992-04-07 | 1992-04-07 | |
US864758 | 1992-04-07 | ||
PCT/EP1992/002231 WO1993007282A1 (en) | 1991-09-30 | 1992-09-28 | New conjugates for the introduction of nucleic acid into higher eukaryotic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2593292A AU2593292A (en) | 1993-05-03 |
AU669335B2 true AU669335B2 (en) | 1996-06-06 |
Family
ID=27419640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU25932/92A Ceased AU669335B2 (en) | 1991-09-30 | 1992-09-28 | New conjugates for the introduction of nucleic acid into higher eukaryotic cells |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP0535576A1 (en) |
JP (1) | JP3479298B2 (en) |
CN (1) | CN1071457A (en) |
AT (1) | ATE187497T1 (en) |
AU (1) | AU669335B2 (en) |
CA (1) | CA2114800A1 (en) |
DE (1) | DE59209778D1 (en) |
FI (1) | FI941473A (en) |
HU (2) | HUT71322A (en) |
IL (1) | IL103059A0 (en) |
MX (1) | MX9205226A (en) |
NO (1) | NO941155D0 (en) |
NZ (1) | NZ244291A (en) |
TW (1) | TW249247B (en) |
WO (1) | WO1993007282A1 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
EP0693939A1 (en) * | 1993-04-14 | 1996-01-31 | Roche Diagnostics GmbH | Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
DE4335025A1 (en) * | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytically active particles |
EP0648493A1 (en) * | 1993-10-19 | 1995-04-19 | Tadatsugu Prof. Dr. Taniguchi | A method to reverse the phenotype of transformed cells by the transcription factor IRF-1 |
DE4426429A1 (en) * | 1994-07-26 | 1996-02-01 | Boehringer Ingelheim Int | Method for introducing DNA into higher eukaryotic cells |
WO1996005307A2 (en) | 1994-08-12 | 1996-02-22 | Myriad Genetics, Inc. | 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
JP2002503943A (en) | 1994-08-12 | 2002-02-05 | ミリアド・ジェネティックス・インコーポレイテッド | In vivo mutations and polymorphisms in 17q-linked breast and ovarian cancer susceptibility genes |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
EP0874910A4 (en) * | 1995-06-07 | 1999-04-21 | Life Technologies Inc | Peptide-enhanced cationic lipid transfections |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
DE69625678T3 (en) | 1995-12-18 | 2006-11-09 | The University Of Utah Research Foundation, Salt Lake City | Chromosome 13 associated breast cancer susceptibility gene BRCA2 |
NZ330744A (en) | 1995-12-22 | 1999-02-25 | Univ Utah Res Found | A long qt syndrome gene which encodes kvlqt1 and its association with mink |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
DE19649645A1 (en) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Multiple functional ligand system for target cell-specific transfer of nucleotide sequences |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
GB9712512D0 (en) | 1997-06-16 | 1997-08-20 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
AU745958B2 (en) | 1997-08-13 | 2002-04-11 | Biontex Laboratories Gmbh | Novel lipopolyamines, and the preparation and use thereof |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
AU9363798A (en) | 1997-11-06 | 1999-05-31 | Chiron S.P.A. | Neisserial antigens |
US6780609B1 (en) | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
CA2317815A1 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
AU4070499A (en) | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
ES2304065T3 (en) | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | ANTIGENS AND COMPOSITIONS OF NEISSERIA MENINGITIDIS. |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
DE19845420C2 (en) * | 1998-10-02 | 2000-11-16 | Deutsches Krebsforsch | Intercellular spread of recombinant DNA |
AU1316200A (en) | 1998-10-15 | 2000-05-01 | Chiron Corporation | Metastatic breast and colon cancer regulated genes |
EP1129064B1 (en) | 1998-11-12 | 2008-01-09 | Invitrogen Corporation | Transfection reagents |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
PT1141331E (en) | 1998-12-16 | 2008-12-22 | Novartis Vaccines & Diagnostic | Human cyclin-dependent kinase (hpnqalre) |
NZ581940A (en) | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
RU2281956C2 (en) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Neisseria antigene peptides |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
CN100473663C (en) | 2000-02-28 | 2009-04-01 | 启龙股份公司 | Heterologous expression of neisserial proteins |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
DE60138403D1 (en) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
US20030093819A1 (en) | 2000-11-03 | 2003-05-15 | D'andrea Alan D. | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
US20030188326A1 (en) | 2000-11-03 | 2003-10-02 | Dana Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
US6875612B2 (en) | 2001-03-30 | 2005-04-05 | Greenville Hospital System | Monocyte-specific particulate delivery vehicle |
AUPR546801A0 (en) | 2001-06-05 | 2001-06-28 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies |
JP4413617B2 (en) | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Immunization against CHLAMYDIATRACHOMATIS |
PL215165B1 (en) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
ATE469984T1 (en) | 2003-12-01 | 2010-06-15 | Life Technologies Corp | NUCLEIC ACID MOLECULES CONTAINING RECOMBINATION SITE AND METHOD FOR USE THEREOF |
WO2005067708A2 (en) | 2004-01-14 | 2005-07-28 | Daniolabs Limited | Zebrafish model for autoimmune diseases |
JP4792390B2 (en) | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | Novel galectin-9 variant protein and use thereof |
AU2005294265A1 (en) | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
EP1856526A4 (en) | 2005-01-20 | 2008-11-12 | Univ Rochester | Thioredoxin interacting protein (txnip) as regulator of vascular function |
JP2009522281A (en) | 2005-12-28 | 2009-06-11 | トランスレーショナル セラピューティクス,インク. | Treatment based on translational dysfunction |
EP2007880A2 (en) | 2006-04-07 | 2008-12-31 | Neuro Therapeutics AB | Survival and development of neural cells |
US7723564B2 (en) | 2006-05-10 | 2010-05-25 | Board Of Regents Of The University Of Nebraska | Compositions and methods for modulation of KSR1 and KSR2 interactions |
PT2054431E (en) | 2006-06-09 | 2011-11-03 | Novartis Ag | Conformers of bacterial adhesins |
US8673859B2 (en) | 2007-03-20 | 2014-03-18 | New York University | GM-CSF cosmeceutical compositions and methods of use thereof |
US8772238B2 (en) | 2009-03-18 | 2014-07-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer |
GB0908425D0 (en) | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
GB201012651D0 (en) | 2010-07-28 | 2010-09-15 | Univ Edinburgh | Peptides |
EP2658567A4 (en) | 2010-12-28 | 2014-09-24 | Univ Rochester | Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides |
DK2753346T3 (en) | 2011-09-07 | 2020-05-25 | Sinai School Medicine | CERAMIDASE AND CELL DIFFERENTIATION |
US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
KR102472590B1 (en) | 2014-05-14 | 2022-11-30 | 타르그이뮨 테라퓨틱스 아게 | Improved polyethyleneimine polyethyleneglycol vectors |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
CN111413499B (en) * | 2020-04-17 | 2023-06-27 | 中国兽医药品监察所 | Indirect immunofluorescence kit for detecting avian adenovirus I group |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
-
1992
- 1992-09-04 IL IL103059A patent/IL103059A0/en unknown
- 1992-09-10 NZ NZ244291A patent/NZ244291A/en unknown
- 1992-09-14 MX MX9205226A patent/MX9205226A/en not_active IP Right Cessation
- 1992-09-21 TW TW081107455A patent/TW249247B/zh active
- 1992-09-28 AU AU25932/92A patent/AU669335B2/en not_active Ceased
- 1992-09-28 CN CN92110625A patent/CN1071457A/en active Pending
- 1992-09-28 CA CA002114800A patent/CA2114800A1/en not_active Abandoned
- 1992-09-28 WO PCT/EP1992/002231 patent/WO1993007282A1/en active IP Right Grant
- 1992-09-28 EP EP92116577A patent/EP0535576A1/en active Pending
- 1992-09-28 AT AT92919852T patent/ATE187497T1/en not_active IP Right Cessation
- 1992-09-28 JP JP50658993A patent/JP3479298B2/en not_active Expired - Fee Related
- 1992-09-28 HU HU9400899A patent/HUT71322A/en unknown
- 1992-09-28 EP EP92919852A patent/EP0606280B1/en not_active Expired - Lifetime
- 1992-09-28 DE DE59209778T patent/DE59209778D1/en not_active Expired - Fee Related
-
1994
- 1994-03-29 NO NO941155A patent/NO941155D0/en unknown
- 1994-03-30 FI FI941473A patent/FI941473A/en unknown
-
1995
- 1995-06-30 HU HU95P/P00695P patent/HU211902A9/en unknown
Non-Patent Citations (2)
Title |
---|
1983 * |
FITZGERALD ET AL: PROC NATL ACAD SCI USA. 80, PP4134-4138, * |
Also Published As
Publication number | Publication date |
---|---|
IL103059A0 (en) | 1993-02-21 |
HU211902A9 (en) | 1996-01-29 |
NO941155L (en) | 1994-03-29 |
FI941473A0 (en) | 1994-03-30 |
AU2593292A (en) | 1993-05-03 |
JP3479298B2 (en) | 2003-12-15 |
TW249247B (en) | 1995-06-11 |
ATE187497T1 (en) | 1999-12-15 |
CN1071457A (en) | 1993-04-28 |
NO941155D0 (en) | 1994-03-29 |
CA2114800A1 (en) | 1993-04-15 |
EP0606280B1 (en) | 1999-12-08 |
FI941473A (en) | 1994-03-30 |
EP0606280A1 (en) | 1994-07-20 |
MX9205226A (en) | 1993-03-01 |
HUT71322A (en) | 1995-11-28 |
DE59209778D1 (en) | 2000-01-13 |
NZ244291A (en) | 1995-07-26 |
HU9400899D0 (en) | 1994-06-28 |
WO1993007282A1 (en) | 1993-04-15 |
JPH07500009A (en) | 1995-01-05 |
EP0535576A1 (en) | 1993-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU669335B2 (en) | New conjugates for the introduction of nucleic acid into higher eukaryotic cells | |
IL103171A0 (en) | Composition for introducing nucleic acid complexes into higher eucaryotic cells | |
WO1992013570A3 (en) | Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis | |
GB2286593A (en) | Virus with modified binding moiety specific for the target cells | |
ATE195144T1 (en) | NEW PROTEIN POLYCATION CONJUGATES | |
ATE318322T1 (en) | VIRAL CORE PROTEINS-CATIONIC LIPID-NUCLIC ACID ADMINISTRATION COMPLEXES | |
Kichler et al. | Efficient gene delivery with neutral complexes of lipospermine and thiol-reactive phospholipids | |
GR3036634T3 (en) | Novel protein polycation conjugates. | |
CA2189051A1 (en) | Composition for delivery of toxic radioisotopes to the cell nucleus and use | |
AU641736B2 (en) | Delivery of agents | |
DE69936348D1 (en) | CONJUGATES OF DNA-BINDING COMPOUNDS WITH STEROID HORMONES AND THEIR USE AS TRANSFECTION AGENTS | |
AU3354795A (en) | Gene-Containing Compositions | |
CDCA | H3. 1 GFP H3. 2 | |
AU1185097A (en) | Improved pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |